BR0013711A - Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos - Google Patents

Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos

Info

Publication number
BR0013711A
BR0013711A BR0013711-1A BR0013711A BR0013711A BR 0013711 A BR0013711 A BR 0013711A BR 0013711 A BR0013711 A BR 0013711A BR 0013711 A BR0013711 A BR 0013711A
Authority
BR
Brazil
Prior art keywords
female
mesoprogestins
progesterone receptor
component
receptor modulators
Prior art date
Application number
BR0013711-1A
Other languages
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of BR0013711A publication Critical patent/BR0013711A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "MESOPROGESTINAS (MODULADORES DE RECEPTORES DE PROGESTERONA) COMO UM COMPONENTE DE CONTRACEPTIVOS FEMININOS". A presente invenção refere-se ao uso de mesoprogestinas para a produção de um produto farmacêutico para contracepção da fêmea, a uma preparação farmacêutica para contracepção da fêmea e a um método de contracepção da fêmea administrando quantidades eficazes de mesoprogestina em uma fêmea desejando contracepção. Optativamente a mesoprogestina pode ser usada em combinação com um estrogênio. Mesoprogestinas são definidas como compostos possuindo ambas as atividades agonista e antagonista no receptor de progesterona (PR) in vivo. Elas estabilizam a função de PR em um nível intermediário de agonista e antagonista. Estados funcionais correspondentes podem ser alcançados com progestinas ou antiprogestinas. J.867, J912, J956 e J1042 são as mesoprogestinas preferidas de acordo com a invenção.
BR0013711-1A 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos BR0013711A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31
PCT/IB2000/002053 WO2001026603A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Publications (1)

Publication Number Publication Date
BR0013711A true BR0013711A (pt) 2002-05-07

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013711-1A BR0013711A (pt) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos

Country Status (28)

Country Link
EP (1) EP1605949A2 (pt)
JP (1) JP2003511399A (pt)
KR (1) KR20020038745A (pt)
CN (1) CN1384748A (pt)
AR (1) AR025455A1 (pt)
AU (1) AU781835B2 (pt)
BG (1) BG106441A (pt)
BR (1) BR0013711A (pt)
CA (1) CA2383650A1 (pt)
CO (1) CO5190694A1 (pt)
CZ (1) CZ2002707A3 (pt)
EA (1) EA006805B1 (pt)
EE (1) EE200200103A (pt)
HR (1) HRP20020265A2 (pt)
HU (1) HUP0202515A3 (pt)
IL (1) IL148415A0 (pt)
LT (1) LT5001B (pt)
LV (1) LV12940B (pt)
MX (1) MXPA02002186A (pt)
NO (1) NO20020998L (pt)
NZ (1) NZ517470A (pt)
PE (1) PE20010579A1 (pt)
PL (1) PL353994A1 (pt)
SI (1) SI20853A (pt)
SK (1) SK2982002A3 (pt)
UA (1) UA77150C2 (pt)
WO (1) WO2001026603A2 (pt)
YU (1) YU13902A (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539016A (ja) * 2002-08-02 2005-12-22 シエーリング アクチエンゲゼルシャフト 女性用受胎調節及びホルモン置換療法のための高められた抗ゴナドトロピン活性を有するプロゲステロン受容体モジュレーター
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
PE20060378A1 (es) * 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
CA2757496A1 (en) 2009-04-14 2010-10-21 Andre Ulmann Method for on-demand contraception
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
ES2061672T3 (es) * 1987-09-24 1994-12-16 Jencap Research Ltd Preparado hormonal y su uso.
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
IL115738A (en) * 1994-10-24 2002-05-23 Schering Ag Competitive progesterone antibodies to regulate female fertility as required
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
AU725670B2 (en) * 1996-06-25 2000-10-19 Akzo Nobel N.V. Progestogen-anti-progestogen regimens
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
EP1175422A2 (en) * 1999-05-04 2002-01-30 Ligand Pharmaceuticals Incorporated Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
PE20010579A1 (es) 2001-06-04
PL353994A1 (en) 2003-12-15
CZ2002707A3 (cs) 2002-11-13
CA2383650A1 (en) 2001-04-19
AU3215001A (en) 2001-04-23
LV12940B (en) 2003-06-20
LT2002035A (lt) 2002-10-25
WO2001026603A2 (en) 2001-04-19
SK2982002A3 (en) 2002-07-02
EA006805B1 (ru) 2006-04-28
BG106441A (bg) 2002-09-30
KR20020038745A (ko) 2002-05-23
AU781835B2 (en) 2005-06-16
EA200200284A1 (ru) 2002-10-31
IL148415A0 (en) 2002-09-12
MXPA02002186A (es) 2002-09-02
HUP0202515A3 (en) 2004-06-28
NO20020998D0 (no) 2002-02-28
WO2001026603A3 (en) 2002-01-17
SI20853A (sl) 2002-10-31
EP1605949A2 (en) 2005-12-21
HUP0202515A2 (hu) 2002-12-28
CO5190694A1 (es) 2002-08-29
NO20020998L (no) 2002-03-14
YU13902A (sh) 2006-01-16
LT5001B (lt) 2003-03-25
CN1384748A (zh) 2002-12-11
JP2003511399A (ja) 2003-03-25
UA77150C2 (en) 2006-11-15
HRP20020265A2 (en) 2004-02-29
EE200200103A (et) 2003-04-15
AR025455A1 (es) 2002-11-27
NZ517470A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
US7723320B2 (en) Use of estrogen compounds to increase libido in women
AU2010339867B2 (en) Nestorone/estradiol transdermal gel
CA2447178C (en) Pharmaceutical composition for use in hormone replacement therapy
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
EP1390041B1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
WO2010118461A1 (en) Gel compositions for administration of pharmaceutically active compounds
US7732430B2 (en) Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
BR9912466A (pt) Utilização de sulfamatos de estrogênio biogênicos na terapia de reposição hormonal
BR0013711A (pt) Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
BR0014952A (pt) Medicamento contraceptivo e seu modo de preparação
BR0013710A (pt) Mesoprogestinas (moduladores de receptor para progesterona) como um componente de composições para a terapia de reposição de hormÈnios (hrt)
WO2001015679A3 (en) Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SCHERING AG (DE)

Free format text: TRANSFERIDO DE: JENAPHARM GMBH AND CO. KG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.